major depressive disorder

This page shows the latest major depressive disorder news and features for those working in and with pharma, biotech and healthcare.

Biogen signs $3.1bn deal with Sage for potential depression therapies

The collaboration and licence agreement will see Biogen and Sage jointly develop and commercialise zuranolone, an investigational treatment for major depressive disorder (MDD), postpartum depression and other psychiatric disorders. ... Major depressive

Latest news

Acadia’s Nuplazid misses the mark in major depressive disorder trial

study for major depressive disorder (MDD), despite showing promise in an earlier, smaller trial. ... We observed a consistent improvement of depressive symptoms over time with Nuplazid but, unfortunately, the robust positive results from our CLARITY-1
Low-dose LSD looks safe for Alzheimer’s patients, but will it work?

Eleusis’ trial comes after the non-profit Usona Institute launched a phase 2 trial of psilocybin – found in ‘magic mushrooms’ – as a treatment for major depressive disorder.
Sage slides off a MOUNTAIN as depression drug flunks trial

The company has just revealed that the pivotal phase 3 MOUNTAIN trial of its drug SAGE-217 – also known as zuranolone – missed its primary endpoint in major depressive disorder (MDD), wiping
Acadia’s drive to extend use of Nuplazid hits a wall

treatment for psychotic symptoms in other diseases, including schizophrenia, dementia and major depressive disorder.
Pear Therapeutics submits latest digital therapeutic, insomnia and depression treatment

SUD). It then followed this up with the approval in December 2018, of reSET-O, for the treatment of Opioid Use Disorder, which it co-markets with Novartis subsidiary Sandoz.. ... to develop a similar CBT-based app for the treatment of major depressive

More from news
Approximately 8 fully matching, plus 57 partially matching documents found.

Latest Intelligence

Leo has its eyes on the prize

condition and the promise of major therapeutic breakthroughs. ... major depressive disorder and iron-deficiency anaemia.
Pharma deals continue to slide

74.5 (upfront 65). Cerecor (US). J&J/Janssen (US). Asset acquisition. CERC-501 phase II oral kappa opioid receptor antagonist for adjunctive treatment of major depressive disorder.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Account Management: Competitive Salary Offered

Home Working Medical Copy Writer & Senior Medical Copy Write...: Highly Competitive Salary, Bonus &Benefits

Medical Writer, Senior Medical Writer, Principal Medical Writer,...: Highly Competitive Salary, Bonus &Benefits

Senior Account Director & Associate Director - Healthcare Ad...: Highly Competitive Salary, Bonus &Benefits

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Senior Content Editor - Biotechnology: Salary TBC

Client Services Director – London or Home Based – Medical Commun...: Highly Competitive Salary, Bonus &Benefits

Editor & Senior Editor - Medical Communications - Home Based: Highly Competitive Salary, Bonus &Benefits

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

PMHub

Add my company

Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story: How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?: The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19: The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...